Apotex Australia Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: Apotex Australia Pharmaceutical Import Records from India — 3 Products, $1.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Apotex Australia — Pharmaceutical Importer Profile (2026) | 3 Products, $1.5M Trade | TransData Nexus

Apotex Australia

Pharmaceutical Importer · Australia · Cardiovascular Focus · $1.5M Total Trade · DGFT Verified

Apotex Australia is a pharmaceutical importer based in Australia with a total trade value of $1.5M across 3 products in 3 therapeutic categories. Based on 115 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Apotex Australia sources from 3 verified Indian suppliers, with Cipla Limited accounting for 67.1% of imports.

Apotex Australia — Import Portfolio & Supplier Network

Apotex Australia import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Apotex Australia?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$6.9M	862	67.1%
Apotex Research Private Limited	$3.1M	213	30.3%
Ipca Laboratories Limited

What Formulations Does Apotex Australia Import?

Formulation	Value	Ships
Apo-levetiracetam 500MG tablets levetiracetam tablets 500MG [14579 Pack x	$271.1K	6
Apo-levetiracetam 500MG tablets levetiracetam tablets 500MG [14544 Pack x	$270.4K	6
Apo-levetiracetam 500 MG tablets	$243.2K	5
Letrozole apotex 2.5 MG tablets	$234.1K	9
Perind arg/amlodipine 5MG/5MG 30 btl	$182.6K	13
Apx-escitalopram (as oxalate) 20 MG	$161.0K	4
Perindopril argi fct 5MG 30 bls gau	$141.3K	3
Apo health childrens ibuprofen 6	$138.3K	14
Apo health childrens ibuprofen 6 month	$135.5K	10
Perindopril erbumine TAB	$129.5K	6
Apo-levetiracetam 250MG tablets levetiracetam tablets 250MG [12601 Pack x	$126.5K	6
Apohealth sleep assist tablets	$102.1K	6
Perindopril argi fct 2.5MG 30 bls gau	$101.3K	4
Perind arg/amlodipine 10MG/10MG 30btl	$100.0K	2
Acamprosate dr ect 333MG 180 bls gau	$92.6K	2

Apotex Australia imports 597 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Simvastatin	Cardiovascular	$672.1K	63	0.5%	15
2	Letrozole	Advanced Oncology	$481.7K	18	1.5%	6
3	Docusate	Gastrointestinal	$329.2K	34	3.6%	5

Apotex Australia imports 3 pharmaceutical products across 3 categories into Australia totaling $1.5M.

Apotex Australia — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Apotex Australia Pty Limited, established in 1991, is a prominent supplier of generic pharmaceuticals, over-the-counter (OTC) products, and vitamins within the Australian pharmacy market. As an affiliate of Apotex Inc., headquartered in Toronto, Canada, Apotex Australia operates under the Australian Company Number (ACN) 054 124 980 and the Australian Business Number (ABN) 48 054 124 980. In July 2019, Apotex Australia merged with Arrow Pharmaceuticals to form Arrotex Pharmaceuticals, creating Australia's largest generic pharmaceutical and private label OTC medicines company. (apotex.com.au)

The merger aimed to provide Australian customers with unparalleled service and support, leveraging the combined strengths of both entities. Apotex Australia continues to play a significant role in the distribution of affordable and accessible medicines across Australia, contributing to the country's healthcare system by offering a diverse portfolio of pharmaceutical products.

2Distribution Network

Apotex Australia's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across Australia. While specific warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive operations suggest a well-established infrastructure capable of supporting nationwide distribution. The merger with Arrow Pharmaceuticals in 2019 likely enhanced their logistics and distribution capabilities, enabling them to serve a broader geographic area within Australia. (apotex.com.au)

3Industry Role

Apotex Australia functions as a primary wholesaler and distributor in the Australian pharmaceutical supply chain. By importing a wide range of generic pharmaceuticals, OTC products, and vitamins, the company ensures the availability of affordable medicines to pharmacies, hospitals, and other healthcare providers across the country. The merger with Arrow Pharmaceuticals in 2019 further solidified its position as a leading player in the Australian pharmaceutical market. (apotex.com.au)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Apotex Australia

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Apotex Australia's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.5 million USD from India across 115 shipments, importing 597 unique formulations. The top three products imported are Simvastatin ($672K), Letrozole ($482K), and Docusate ($329K), accounting for 45.3%, 32.5%, and 22.2% of the total import value, respectively. This concentration indicates a strategic focus on specific therapeutic areas, particularly in cardiovascular, oncology, and gastrointestinal treatments.

The primary suppliers from India include CIPLA LIMITED ($6.9M, 67.1% of shipments), APOTEX RESEARCH PRIVATE LIMITED ($3.1M, 30.3% of shipments), and IPCA LABORATORIES LIMITED ($263K, 2.6% of shipments). The significant share held by CIPLA LIMITED and APOTEX RESEARCH PRIVATE LIMITED suggests strong, stable relationships with these suppliers. However, the high concentration also poses a potential risk; any disruptions with these suppliers could impact Apotex Australia's ability to meet market demand.

2Supply Chain Resilience

Apotex Australia's supply chain resilience is closely tied to its sourcing strategy. The heavy reliance on a few key suppliers from India, particularly CIPLA LIMITED and APOTEX RESEARCH PRIVATE LIMITED, indicates a need for robust contingency planning. While the company imports a diverse range of 597 unique formulations, the concentration of imports in specific therapeutic areas suggests that any supply chain disruptions could have a significant impact on product availability. Ensuring compliance with international quality standards, such as WHO GMP, and maintaining strong relationships with multiple suppliers could enhance supply chain resilience.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the Therapeutic Goods Administration (TGA) is the primary regulatory authority responsible for overseeing the importation, supply, and regulation of therapeutic goods, including pharmaceuticals. The TGA operates under the Therapeutic Goods Administration Act 1989, which provides the legislative framework for the regulation of medicines and medical devices in Australia. (legislation.gov.au)

For Indian pharmaceutical companies seeking to export to Australia, obtaining marketing authorization from the TGA is essential. This process involves submitting a comprehensive application that includes product information, evidence of quality and efficacy, and compliance with Australian standards. The TGA evaluates these submissions to ensure that imported medicines meet the required safety, quality, and efficacy standards before they can be marketed in Australia.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Australia are stringent. Indian exporters must ensure that their manufacturing facilities hold valid Good Manufacturing Practice (GMP) certifications recognized by the TGA. Certifications from reputable bodies such as the European Union (EU) GMP, World Health Organization (WHO) GMP, or the Pharmaceutical Inspection Co-operation Scheme (PIC/S) are typically accepted. Additionally, Indian exporters must obtain a wholesale distribution authorization to supply medicines in Australia, ensuring compliance with local regulations and standards.

Apotex Australia — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Apotex Australia's product strategy focuses on high-demand therapeutic areas, particularly cardiovascular, oncology, and gastrointestinal treatments. The company's import portfolio includes key products such as Simvastatin, Letrozole, and Docusate, which align with prevalent health conditions in Australia. This strategic focus is driven by market demand for affordable and effective treatments in these therapeutic categories.

2Sourcing Profile

Apotex Australia's sourcing strategy emphasizes generic drugs, with a preference for formulations that address common and chronic health conditions. India plays a crucial role in their procurement strategy, providing a diverse range of high-quality generic pharmaceuticals that meet Australian regulatory standards. This sourcing approach enables Apotex Australia to offer cost-effective treatment options to the Australian market.

3Market Positioning

Apotex Australia's product mix positions it as a key supplier to various segments of the Australian pharmaceutical market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. By offering a comprehensive portfolio of generic pharmaceuticals and OTC products, the company caters to a broad spectrum of healthcare providers and patients, ensuring access to essential medicines across the country.

Seller's Guide — How to Become a Supplier to Apotex Australia

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Australian market by meeting the stringent regulatory requirements set by the TGA and aligning their product offerings with the therapeutic areas prioritized by Apotex Australia. Gaps in Apotex Australia's current sourcing may exist in emerging therapeutic areas or novel formulations, presenting opportunities for Indian exporters to introduce innovative products that complement the existing portfolio.

2Requirements & Qualifications

Indian exporters seeking to supply Apotex Australia and the broader Australian market must obtain GMP certifications recognized by the TGA, such as EU GMP, WHO GMP, or PIC/S. They must also secure import licenses and wholesale distribution authorizations, ensuring compliance with Australian regulations. Additionally, products must meet Australian quality standards, including batch testing, stability requirements, and labeling in English with specific information.

3How to Approach

Frequently Asked Questions — Apotex Australia

What products does Apotex Australia import from India?

Apotex Australia imports 3 pharmaceutical products across 3 categories. Top imports: Simvastatin ($672.1K), Letrozole ($481.7K), Docusate ($329.2K).

Who supplies pharmaceuticals to Apotex Australia from India?

Apotex Australia sources from 3 verified Indian suppliers. The primary supplier is Cipla Limited (67.1% of imports, $6.9M).

What is Apotex Australia's total pharmaceutical import value?

Apotex Australia's total pharmaceutical import value from India is $1.5M, based on 115 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Apotex Australia focus on?

Apotex Australia imports across 3 categories. The largest: Cardiovascular (45.3%), Advanced Oncology (32.5%), Gastrointestinal (22.2%).

Get Full Apotex Australia Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.